PALBOCICLIB REAL WORLD DATA IN ADVANCED AND METASTATIC BREAST CANCER TREATED: A MULTICENTER EXPERIENCE IN LEBANON
treated with palbociclib + ET in second and third lines (28.5% and 30.5%, respectively). Other pts received palbociclib in ≥4th lines. In 24,8% pts (26/105) palbociclib was combined with aromatase inhibitors, in other cases – with fulvestrant. Median follow-up time was 6.5 months (1.1–31.9), median progression free survival – 6.0 months (1.0–28.0). The median follow-up
Read more